|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From Klinik für Innere Medizin I, Zentrum
für Molekulare Medizin der Universität Köln, Germany;
Institut für Biochemie RWTH-Klinikum Aachen, Germany; and
Eberhard-Karls-Universität Tübingen, Institut für
Tropenmedizin, Sektion für Humanparasitologie, Germany.
Hodgkin disease (HD) represents a malignant lymphoma in which the
putative malignant Hodgkin and Reed-Sternberg cells are rare and
surrounded by abundant reactive nonmalignant cells. It has been
suggested that cytokines such as interleukin-6 (IL-6) are involved in
the pathogenesis of the disease. The expression of the IL-6 receptor
(IL-6R) complex and its link to the activation of signal transducers
and activators of transcription (STAT) molecules in HD cell lines was
investigated. Gel retardation and Western blot analyses revealed a high
level of constitutively activated STAT3 in 5 of 7 HD cell lines, which
could not be detected in Burkitt lymphoma cell lines. Different levels
of IL-6R protein were measured in various HD cell lines: L428 and Dev
cells were characterized by very low levels of gp80 and gp130, on KMH2
cells only gp130 but no gp80 was detected, whereas L540, L591, HDLM2, and L1236 were positive for both gp80 and gp130, suggesting a possible
autocrine stimulation of STAT3. However, a further increase in STAT3
activation on IL-6 or IL-6/soluble IL-6R stimulation was
not observed. Neutralizing monoclonal antibodies against IL-6, gp80,
gp130, or both receptor subunits did not affect the proliferation or
the constitutive activation of STAT molecules in HD cell lines. However, the tyrosine kinase inhibitor AG490 blocked the constitutive activation of STAT3 and inhibited spontaneous growth of HD tumor cells.
The evidence suggests abnormal STAT signaling and growth regulation in
Hodgkin cell lines.
(Blood. 2001;98:762-770) Hodgkin disease (HD) is characterized by a
disruption of the lymph node architecture with low numbers of
Hodgkin and Reed-Sternberg (H-RS) cells surrounded by an abundance of
reactive nonmalignant cells.1,2 This histologic pattern of
HD may be due to the production and release of cytokines from H-RS
cells that are involved in the growth of the lymphoma cells and the
interactions with bystander cells.3-5
Recently it has been shown that HD cell lines and primary H-RS cells
express interleukin-6 (IL-6) and the To further explore the putative role of IL-6 in HD, the expression of
gp130 and the influence on the activation of STAT proteins in HD cell
lines was analyzed. Neutralizing monoclonal antibodies against IL-6,
gp80, gp130, or both receptor subunits did not affect the proliferation
of the HD cells or the constitutive activation of STAT molecules.
However, the tyrosine kinase inhibitor AG490 inhibited both the
constitutive activation of STAT3 and the growth of Hodgkin cell lines
in vitro.
Cell lines
Cytokines
Immunostaining of proteins For Western blot analysis cells were harvested and washed with PBS. The cellular extracts were prepared in 2 × Laemmli buffer, boiled for 10 minutes, and chilled on ice. Proteins were separated on a discontinuous sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) with a 7.5% acrylamide resolving gel, before electroblotting onto nitrocellulose filters (Hybond C extra, Amersham-Pharmacia, Freiburg, Germany). Equal loading of the gels was verified by Ponceau S staining. After incubation with blocking buffer for 1 hour, the blots were incubated with monoclonal mouse -gp130 B-T12 (1 µg/mL) overnight at 4°C, washed 3 times with
triethanolamine-buffered saline (TBS)/0.05% Tween and
incubated with the peroxidase-coupled second antibodies (goat -mouse
horseradish peroxidase [HRP; Dako, Hamburg, Germany]).16
The blots were developed using the enhanced chemiluminescence (ECL)
system (Amersham-Pharmacia) according to the manufacturer's instructions.
Phosphorylated STAT3 proteins were detected by Western blot analysis
separating 20 µg nuclear extracts on a discontinuous SDS-PAGE with a
10% acrylamide resolving gel, before electroblotting onto
nitrocellulose filters (Hybond C extra). Equal loading of the gels was
verified by Ponceau S staining (Biorad, München, Germany). After
incubation with blocking buffer for 1 hour the blots were incubated
with a rabbit polyclonal antibody directed against phospho-specific
STAT3 (New England Biolabs, Schwalbach, Germany) at a dilution 1:1000
overnight at 4°C, washed 3 times with TBS/0.05% Tween, and incubated
with the peroxidase-coupled second antibodies (goat Immunofluorescence analysis For detection of cell surface antigen expression, 1 × 106 cells were washed twice in PBS supplemented with 0.5% BSA. Cells were incubated with monoclonal antibodies (5-10 µg/mL) for 10 minutes on ice in the dark. Cells were washed with PBS, 0.5% BSA, and stained with phycoerythrin (PE)-conjugated goat-mouse Ig antibodies.33,34
Monoclonal antibodies used and their sources were as follows: IL-6-enzyme-linked immunosorbent assay Cells (5 × 105/mL) were cultured for 24 hours in RPMI 1640 complete medium. The IL-6 content in the supernatants was measured by a specific enzyme-linked immunosorbent assay (ELISA) (Diaclone). The lower detection level of this ELISA was 3.5 pg/mL.Analysis of cell proliferation DNA synthesis of cultured L428 HD cells (1 × 105 cells/well) was monitored by 3H-thymidine incorporation (0.4 µCi/well) (Amersham-Pharmacia) during the last 16 hours of culture in the absence or presence of the tyrphostin AG490 at 50 µM or 100 µM (Calbiochem, Schwalbach, Germany). The tyrphostin was solved in DMSO. The cells cultured in the absence of the tyrphostin were incubated with a corresponding amount of DMSO as control. Cells were harvested and analyzed by liquid scintillation counting (Beckmann, Düsseldorf, Germany). Data are presented as relative inhibition of proliferation plus SD of triplicate measurements. The proliferation of L428 cells in the presence of DMSO was taken as 100%. Parallel cultures were analyzed for STAT3 and STAT1 activation.Gel retardation assays Nuclear extracts were prepared as described.35 Protein concentrations were measured using the Biorad protein assay (Bradford, Biorad). A double-stranded mutated SIE (sis-inducible element)-oligonucleotide from the c-fos promoter (m67SIE) was labeled by filling in 5' protruding ends with the Klenow enzyme, using (-32P)dATP (3.000 Ci/mmol; 10 mCi/mL [Amersham-Pharmacia]). Nuclear extracts containing 5 µg
protein were incubated with about 10 fmol (10 000 cpm) of
probe in gel shift incubation buffer: 10 mM HEPES pH 7.8, 1 mM
ethylenediaminetetraacetic acid (EDTA), 5 mM MgCl2,
10% glycerol, 5 mM dithiothreitol, 0.7 mM phenylmethylsulfonyl fluoride, 0.1 mg/mL poly(dI-C), and 1 mg/mL BSA for 10 minutes at room
temperature. The protein-DNA complexes were separated on a 4.5%
polyacrylamide gel containing 7.5% glycerol in 0.25-fold triethanolamine-borat-EDTA (TBE) at 20 V/cm for 4 hours. Gels were fixed in a water solution of 10% methanol and 10% acetic acid
for 30 minutes, dried, and autoradiographed on Kodak-Biomax films
(Sigma-Aldrich). Oligonucleotides used were purchased from Eurogentec
(Serain, Belgium) with the following sequences (lower case
letters indicate the cohesive ends of the double-stranded oligonucleotide used for Klenow labeling, the mutations are given in
underlined italics): human c-fos promoter.
STAT1/3 (m67SIE): 5' gatcCGGGAGGGATTTACGGGAAATGCTA; STAT1/3M1: 5' gatcCGGGAGGGATTTACGCTAGATGCTA; STAT1/3M2: 5' gatcCGGGAGGCTAGTACGGGAAATGCTA; STAT1/3M3: 5' gatcCGGCTAGGATTTACGGGAAATGCTA.35,36 Supershift antibodies against STAT1 (clone E-23), STAT3 (clone H-190), STAT5 (clone G-2), and PEA1 (clone L-173; PEA1 is an unrelated transcription factor and used as negative supershift control) were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). Supershifts were performed by incubating the nuclear extracts with the corresponding antibody before adding the radiolabeled oligonucleotide to the binding reaction mixture and incubating them for 45 minutes at room temperature.
STAT3 is constitutively activated in Hodgkin cells It has been shown previously that IL-6 and the IL-6R gp80 are expressed in H-RS cells. The binding of IL-6 to its receptor subunit gp80 is usually followed by an association of the IL-6/gp80 complex with 2 gp130 molecules. The formation of the high-affinity IL-6/IL-6R/gp130 complex is accompanied by the rapid activation of Janus kinases and STAT proteins. In some cases, however, it has been reported that STAT molecules are constitutively active in transformed cells. To analyze whether STAT proteins are constitutively activated in HD cell lines, gel retardation experiments (electrophoretic mobility shift assay [EMSA]) were performed. Nuclear extracts from untreated Hodgkin cells formed protein-DNA complexes with the promoter element of the c-fos gene as detected by EMSA (Figure 1A). The intensity of the retarded bands varied between the different cell lines: L1236, L428, L591, L540, and HDLM2 cells were characterized by intense bands, whereas KMH2 and Dev cells showed only weak bands in the EMSA. In L428, L591, and L1236 cells the protein-DNA complexes comigrated with those induced by IL-6 in HepG2 hepatoma cells, previously identified as STAT3/3 and STAT3/1 and STAT1/1 homodimers and heterodimers. In L540 and HDLM2 cells the STAT3/3 homodimer was dominant. Repeated experiments showed that STAT3/3 homodimers were regularly detected, whereas STAT1/1 homodimers were not always visible in the EMSA.
The same Hodgkin cell lines were analyzed by Western blot experiments for the presence of phosphorylated and unphosphorylated STAT3 using corresponding specific antibodies (Figure 1B,C). Nuclear extracts (20 µg) from untreated Hodgkin cells were analyzed, demonstrating that only in those cells with specific protein-DNA complexes was phosphorylated STAT3 detected, whereas unphosphorylated STAT3 was expressed at comparable amounts in all HD cell lines analyzed (Figure 1C). In 2 representative HD cell lines, L428 (Figure
2A) and L540 (Figure 2B), we tested the
specificity of the protein-DNA interaction by competition with
unlabeled oligonucleotides and with supershift assays. The incubation
of nuclear extracts from L428 HD cells with an excess of unlabeled
STAT1/3 oligonucleotides resulted in the disappearance of the STAT1 and
STAT3 bands in EMSA (Figure 2A, lane 2), whereas in experiments with
nuclear extracts from L540 HD cells the dominant STAT3/3 homodimer band
disappeared (Figure 2B, lane 2). With oligonucleotide M1 containing
point mutations in the core STAT binding site ("GGAA" to
"CTAG") no competition was detected (Figure 2A,B, lanes 3).
Accordingly, when oligonucleotide M1 was used as the radiolabeled probe
for gel retardation experiments no DNA-STAT complexes were formed (Figure 2A, lanes 5-8; Figure 2B, lanes 6-10). Mutations nearby or
outside the core binding sequence for STAT1 and STAT3 in
oligonucleotides M2 and M3 did not interfere with binding and
competition was observed (Figure 2A,B, lanes 4; Figure 2B, lane 5).
Antibodies directed against STAT1 or against STAT3 disrupted the
respective DNA-protein complexes in nuclear extracts isolated from L428
cells (Figure 2A, lanes 9 and 10) and L540 cells (Figure 2B, lanes 11 and 12). The interaction of STAT3 with the corresponding site in the
STAT1/3 oligonucleotide is very strong because the supershift antibody directed against STAT3 induced a supershift, but still there remained a
DNA-protein complex visible (Figure 2B, lane 12). In these experiments in L428 cells the STAT1/1 homodimer-containing band was not as clearly
visible as in the experiments shown in Figure 1. The antibodies directed against STAT5 or PEA1 used as specificity controls did not
react with nuclear extracts from HD cell lines in EMSA (Figure 2A,
lanes 11 and 12; Figure 2B, lanes 13 and 14). Taken together these
experiments show that nuclear extracts from untreated HD cells contain
activated STAT3 homodimers and heterodimers and to a much lower extent
STAT1 homodimers, suggesting constitutive activation of these
transcription factors in HD.
Comparison of STAT1 and STAT3 activation in Hodgkin, non-Hodgkin lymphoma, and acute leukemia cell lines It has been described that myeloma and myeloid leukemia cell lines are characterized by constitutively activated STAT proteins.13,24 To analyze whether the constitutive STAT activation can also be observed in other hematopoetic malignant cells the DNA-protein interactions of nuclear extracts from HD, BL, multiple myeloma, and leukemia cell lines were compared in EMSA. The following cell lines were included in the analysis: chepBL and mutucl59 are EBV+ type I BL cell lines, BL60 is an EBV+ type II BL cell line, BL2 and DG75 are EBV BL cell lines, and
BJAB is derived from a BL lacking the myc-Ig translocation, which is
typical for BL. Jurkat is an acute T-cell leukemia cell line. OciAML2
and NB4 are cell lines from AML and U266 from multiple myeloma. No
specific activation of STAT1 and STAT3 was detected in BL cell lines,
NB4 AML cells, and Jurkat T-leukemia cells. However, nuclear extracts
from U266 multiple myeloma cells and OciAML2 cells contained
DNA-binding activities similar to those detected in the various HD
cells and IL-6-stimulated hepatoma cells (Figure
3). Thus, constitutive activation of
STAT3 (and STAT1) is not confined to HD cells and can also be observed in AML and myeloma cells, whereas in BL cells no activation of STAT1
and STAT3 was found.
IL-6R (gp80) and gp130 are expressed on HD cell lines Because IL-6 is produced by Hodgkin cell lines, the binding of IL-6 to its receptor could be responsible for STAT3 activation. IL-6R gp80 chains have been detected in Hodgkin cell lines and primary H-RS cells. The expression of gp130, which is essential for intracellular signaling, was analyzed by Western blot analysis using the-gp130 antibody B-T12. The myeloma cell line U266, which served
as a positive control for gp130 expression, and the HD cell lines KMH2,
Dev, L540, and L591, expressed gp130, whereas L428, L1236, and HDLM2
were negative for gp130 expression in Western blot analysis (Figure
4A). In the HD cell line KMH2 an
additional faint band of higher mobility was detected suggesting the
existence of a truncated gp130 molecule (Figure 4A, gp130*). Size
differences of gp130 (Figure 4A, gray bar) may be due to different
degrees of glycosylation.
The expression of gp130 was analyzed by flow cytometry with
indirect staining ( The expression of gp130 was compared with the expression of IL-6R
(gp80)
Constitutive STAT3 activation in HD cell lines does not depend on gp130 or IL-6 Interleukin-6 together with sIL-6R is able to enhance IL-6-mediated signals by directing IL-6 to the gp130 signal transducer independently of the expression level of gp80 on the cell surface. To test whether IL-6 and sIL-6R can further enhance the observed STAT activity in HD cells, L540 and L1236 cells were incubated with IL-6 in the presence or absence of sIL-6R. No difference was observed between the DNA-binding activities of nuclear extracts prepared from cells incubated in the presence of exogenous IL-6 alone or together with sIL-6 receptor (Figure 5). Similar results were obtained for L428 cells (data not shown).
To test whether IL-6, gp80, or gp130 is involved in the observed STAT3
activation or may influence the proliferation of the HD cells, the cell
lines L428, L540, and L1236 were incubated with
The proliferation of these cell lines could not be inhibited in the
presence of neutralizing antibodies against IL-6, gp80, and gp130 as
measured by 3H-thymidine incorporation after 5 days of
antibody incubation (data not shown). This is in line with earlier
experiments in which we found that the growth of HD cells, which
produce IL-6 and express the IL-6R gp80, could not be inhibited by
The tyrphostin AG490 inhibits STAT3 activation and growth of the Hodgkin cell line L428 Recently it was shown that tyrphostin AG490 is a Jak2 inhibitor leading to inhibition of constitutively activated STAT3 molecules in acute leukemias and multiple myeloma. Thus it was analyzed whether AG490 affects the constitutive activation and the proliferation of HD cell lines. Cells were incubated with AG490 and analyzed for STAT3 activation 6 and 24 hours after incubation with AG490. Nuclear extracts from untreated HD cells formed protein-DNA complexes with the promoter element of the c-fos gene as detected by EMSA, whereas the AG490-treated cells showed drastically reduced amounts of specific protein-DNA complexes (Figure 7A). The use of specific STAT3-phosphotyrosine antibodies demonstrates that 24 hours after incubation with the tyrphostin the phosphorylation of tyrosines on STAT3 was completely blocked, whereas STAT3 protein level was unaltered (Figure 7B,C). After 3 days the proliferation was tested. As measured by 3H-thymidine incorporation, the proliferation of L428 cells was completely inhibited by AG490 (Figure 7D). Thus the Jak-inhibitor tyrphostine AG490 blocked the constitutive activation of STAT3 and inhibited spontaneous growth of HD tumor cells.
Biochemical and molecular analysis of HD is still hampered by the fact that very low numbers of H-RS cells are surrounded by a variety of reactive cells.2,34 Recent analyses revealed that H-RS cells are derived from B cells in the germinal center and are characterized by rearranged, somatically hypermutated Ig genes that are frequently nonfunctional.2 The mechanism responsible for the oncogenic transformation is still unknown. Interestingly, H-RS cells express a variety of cytokines and cytokine receptors that may regulate interactions between tumor cells and reactive cells.3 Constitutive expression of growth factors may lead to unlimited proliferation in certain tumor cells. We and other groups have previously shown that IL-6 and IL-6R gp80 are expressed both in HD cell lines and in primary H-RS cells and IL-6, and perhaps additional cytokines may be involved in the pathogenesis of HD.1,3-6 The aim of this study was to evaluate whether IL-6 signal transduction is important for the growth of HD cell lines. Using a panel of well-characterized HD cell lines we identified constitutively activated DNA-binding proteins in these cells. Competition experiments with unlabeled oligonucleotides and supershift assays revealed that the DNA-binding proteins in the nuclear extracts from HD cell lines contain STAT3 and, at lower levels, STAT1. The HD cell lines differ in expression levels of gp80, gp130, and IL-6. However, incubation with IL-6 in the presence or absence of sIL-6R did not increase the DNA-binding activity of STAT factors. Activation of STAT was independent of endogenous IL-6 as shown by neutralization experiments. Thus, STAT activation was already high without stimulation by exogenous factors. In addition antibodies against IL-6, IL-6R, or gp130 did not inhibit the DNA-binding activity of STAT3. This reveals that IL-6-type cytokines such as IL-6, IL-11, leukemia inhibitory factor, oncostatin M, ciliary neurotrophic factor, and cardiotrophin are not involved in the observed constitutive activation of STAT3 in HD cells.8 It is unlikely that soluble factors from the culture medium are responsible for the observed STAT activation because incubation of the cells in starvation medium did not reduce STAT activity. We formally cannot exclude that HD cells produce a factor-mediating activation of a receptor resulting in STAT activation, although exchange of the conditioned medium with fresh medium did not alter STAT activation (data not shown). Interleukin-6 is the major survival factor for multiple myeloma tumor cells where STAT3 is constitutively activated. In the multiple myeloma cell line U266 blocking of the IL-6R signaling from Janus kinases to STAT3 inhibits Bcl-x expression and induces apoptosis, providing evidence that constitutively activated STAT3 contributes to the pathogenesis of multiple myeloma.13 It has been hypothesized that genes regulated by STAT3 act cooperatively in cell cycle progression and prevention of apoptosis in BAF-BO3 cells.55,56 However, in a melanoma cell line the opposite effect was detected in that IL-6 was involved in STAT-dependent growth inhibition by up-regulating p27/Kip1.57 Furthermore, evidence suggests that gp130 can induce opposite pathways at least in certain cells.58,59 However it has been reported by several authors that constitutively activated STAT molecules can be detected in acute leukemic cells and bone marrow mononuclear cells from patients with multiple myeloma.13,24,25,28,38 In a recent report it has been shown in addition that the substitution of 2 cysteines in STAT3 led to a spontaneous activation that by itself can mediate cellular transformation.39 Here we show that STAT proteins are constitutively activated in HD. This deregulated STAT activation could be due either to gp130-independent activation of Jak or other tyrosine kinases.40-42 The deregulation of the Jak/STAT pathway has been recently described in a T-acute lymphocytic leukemia (ALL) line, in which a t(9;12) chromosomal translocation led to a TEL-Jak2 fusion protein. TEL-mediated oligomerization of TEL-Jak2 resulted in the constitutive activation of its tyrosine kinase activity and conferred cytokine-independent proliferation to the IL-3-dependent Ba/F3 cell line.27 Recent studies indicated that intracellular events may influence the activation of STAT proteins, thereby rendering the cells to grow independently of extracellular stimuli. It has been described that src can activate STAT directly without Jak.43-46 Other proto-oncogenes like Eyk, Bmx, v-abl, or the bcr-abl fusion protein can also activate the Jak/STAT pathway using bypass mechanisms to activate cytokine signal transduction pathways and promote transformation.26,47-49 Thus, oncogenes not yet identified could be responsible for the activation of STAT molecules in HD. HD cell lines as well as primary H-RS cells so far analyzed indeed show a heterogeneous pattern of proto-oncogene expression and gene translocations including aberrant c-fes transcripts.50,51 Alternatively, inhibitors of STAT activation such as SOCS and PIAS may be absent or suppressed in HD cells. Thus, the analysis of potential mutations in proteins involved in the activation or inactivation of STAT proteins, or the identification of translocations leading to constitutive STAT activating kinases, may be an object of further investigation in HD. Recently it was shown that the Jak2 gene is amplified in Hodgkin cells, which could be responsible for constitutive STAT3 activation.60 However, we could not demonstrate the overexpression or enhanced activation of Jak2 compared to other Janus kinases (data not shown). Recently it was shown that HD cells contain constitutively
activated nuclear factor (NF)- We have shown that in the HD cell line L428 the constitutively activated STAT3 could be inhibited by the tyrphostin AG490, which also inhibits the proliferation of the cells. Recently it has been shown that AG490 selectively blocks STAT activation in primary pre-B ALL, cutaneous T-cell lymphomas, and the myeloma cell line U266. In these cell lines AG490 also inhibited the proliferation of the tumor cells indicating a link between cell proliferation and constitutively activated STAT molecules.13,25,28,39 AG490 is a protein tyrosine kinase inhibitor that inhibits Jak2 and perhaps other kinases. We analyzed the activation of several Jaks in HD cell lines using Western blot analyses. Our preliminary results show that a number of Janus kinases are phosphorylated in HD cell lines independent of whether they contain activated STAT3 or not (data not shown). However, STAT3 could also be activated by different mechanisms including the activation of src kinases or the lack of STAT3 inhibitors. The fact that the STAT3 activation is inhibited by a tyrosine kinase inhibitor makes it less probable that a mutation might be the reason for constitutive activation.39 In conclusion, we have identified constitutively activated STAT3 in Hodgkin cell lines. The observed STAT activation may render H-RS cells to grow independently of STAT-activating factors and support the notion that activated STAT proteins participate in oncogenic transformation.
We would like to acknowledge A. Jox and G. Mosialos for helpful discussions on the manuscript and H. Straub for technical assistance.
Submitted June 25, 1999; accepted February 27, 2001.
Supported by grants from the Deutsche Forschungsgemeinschaft within the Sonderforschungsbereich 502 (Cologne), the Köln Fortune Program-Faculty of Medicine University of Cologne and the Sonderforschungsbereich 542 (Aachen).
D.K. and U.H. contributed equally to this article.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Dieter Kube, Eberhard-Karls-Universität, Institut für Tropenmedizin, Sektion für Humanparasitologie, Wilhelmstraße 27, D-72074 Tübingen, Germany; e-mail: dieter.kube{at}uni-tuebingen.de.
1. Poppema S. Immunology of Hodgkin's disease. Baillieres Clin Haematol. 1996;9:447-457[CrossRef][Medline] [Order article via Infotrieve]. 2. Küppers R, Rajewsky K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu Rev Immunol. 1998;16:471-493[CrossRef][Medline] [Order article via Infotrieve].
3.
Jücker M, Abts H, Li W, et al.
Expression of interleukin-6 and interleukin-6 receptor in Hodgkin's disease.
Blood.
1991;77:2413-2418 4. Klein S, Jücker M, Diehl V, Tesch H. Production of multiple cytokines by Hodgkin's disease derived cell lines. Hematol Oncol. 1992;10:319-329[Medline] [Order article via Infotrieve]. 5. Herbst H, Samol J, Foss HD, Raff T, Niedobitek G. Modulation of interleukin-6 expression in Hodgkin and Reed-Sternberg cells by Epstein-Barr virus. J Pathol. 1997;182:299-306[CrossRef][Medline] [Order article via Infotrieve]. 6. Foss HD, Herbst H, Oelmann E, et al. Lymphotoxin, tumour necrosis factor and interleukin-6 gene transcripts are present in Hodgkin and Reed-Sternberg cells of most Hodgkin's disease cases. Br J Haematol. 1994;84:627-635. 7. Taga T, Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol. 1997;15:797-819[CrossRef][Medline] [Order article via Infotrieve]. 8. Heinrich PC, Behrmann I, Müller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J. 1998;334:297-314.
9.
Muraguchi A, Hirano T, Tang B, et al.
The essential role of B cell stimulatory factor 2 (BSF-2/IL-6) for the terminal differentiation of B cells.
J Exp Med.
1988;167:332-344 10. Kawano M, Hirano T, Matsuda T, et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988;332:83-85[CrossRef][Medline] [Order article via Infotrieve].
11.
Tosato G, Tanner J, Jones KD, Revel M, Pike SE.
Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells.
J Virol.
1990;64:3033-3041 12. Zubler RH. Key differentiation steps in normal B cells and in myeloma cells. Semin Hematol. 1997;34:13-22[Medline] [Order article via Infotrieve]. 13. Catlett-Falcone R, Landowski TH, Oshiro MM, et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 1999;10:105-115[CrossRef][Medline] [Order article via Infotrieve]. 14. Hibi M, Nakajima K, Hirano T. IL-6 cytokine family and signal transduction: a model of the cytokine system. J Mol Med. 1996;74:1-12[CrossRef][Medline] [Order article via Infotrieve]. 15. Klein SC, Jücker M, Abts H, Tesch H. IL6 and IL6 receptor expression in Burkitt's lymphoma and lymphoblastoid cell lines: promotion of IL6 receptor expression by EBV. Hematol Oncol. 1995;13:121-130[Medline] [Order article via Infotrieve]. 16. Wijdenes J, Heinrich PC, Müller-Newen G, et al. Interleukin-6 signal transducer gp130 has specific binding sites for different cytokines as determined by antagonistic and agonistic anti-gp130 monoclonal antibodies. Eur J Immunol. 1995;25:3474-3481[Medline] [Order article via Infotrieve].
17.
Lütticken C, Wegenka UM, Yuan J, et al.
Association of transcription factor APRF and protein kinase Jak1 with the interleukin-6 signal transducer gp130.
Science.
1994;263:89-92
18.
Stahl N, Boulton TG, Farruggella T, et al.
Association and activation of Jak-Tyk kinases by CNTF-LIF-OSM-IL-6 beta receptor components.
Science.
1994;263:92-95
19.
Darnell JJ.
STATs and gene regulation.
Science.
1997;277:1630-1635
20.
Horvath CM, Wen Z, Darnell JJ.
A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain.
Genes Dev.
1995;9:984-994 21. Sasse J, Hemmann U, Schwartz C, et al. Mutational analysis of acute-phase response factor/Stat3 activation and dimerization. Mol Cell Biol. 1997;17:4677-4686[Abstract].
22.
Gerhartz C, Heesel B, Sasse J, et al.
Differential activation of acute phase response factor/STAT3 and STAT1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130, I: definition of a novel phosphotyrosine motif mediating STAT1 activation.
J Biol Chem.
1996;271:12991-12998
23.
Weber-Nordt R, Egen C, Wehinger J, et al.
Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines.
Blood.
1996;88:809-816
24.
Gouilleux GV, Gouilleux F, Desaint C, et al.
STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients.
Blood.
1996;87:1692-1697 25. Meydan N, Grunberger T, Dadi H, et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature. 1996;379:645-648[CrossRef][Medline] [Order article via Infotrieve]. 26. Chai SK, Nichols GL, Rothman P. Constitutive activation of JAKs and STATs in BCR-Abl-expressing cell lines and peripheral blood cells derived from leukemic patients. J Immunol. 1997;159:4720-4728[Abstract].
27.
Lacronique V, Boureux A, Valle VD, et al.
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Science.
1997;278:1309-1312
28.
Nielsen M, Kaltoft K, Nordahl M, et al.
Constitutive activation of a slowly migrating isoform of Stat3 in mycosisfungoides: tyrphostin AG490 inhibits Stat3 activation and growth of mycosisfungoides tumor cell lines.
Proc Natl Acad Sci U S A.
1997;94:6764-6769
29.
Xia Z, Baer MR, Block AW, Baumann H, Wetzler M.
Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts.
Cancer Res.
1998;58:3173-3180 30. Falk MH, Tesch H, Stein H, et al. Phenotype versus immunoglobulin and T-cell receptor genotype of Hodgkin-derived cell lines: activation of immature lymphoid cells in Hodgkin's disease. Int J Cancer. 1987;40:262-269[Medline] [Order article via Infotrieve].
31.
Wolf J, Kapp U, Bohlen H, et al.
Peripheral blood mononuclear cells of a patient with advanced Hodgkin's lymphoma give rise to permanently growing Hodgkin-Reed Sternberg cells.
Blood.
1996;87:3418-3428 32. Weiergräber O, Hemmann U, Küster A, et al. Soluble human interleukin-6 receptor: expression in insect cells, purification and characterization. Eur J Biochem. 1995;234:661-669[Medline] [Order article via Infotrieve].
33.
Kube D, Vockerodt M, Weber O, et al.
Expression of Epstein-Barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428.
J Virol.
1999;73:1630-1636
34.
Irsch J, Nitsch S, Hansmann Martin L, et al.
Isolation of viable Hodgkin and Reed-Sternberg cells from Hodgkin disease tissues.
Proc Natl Acad Sci U S A.
1998;95:10117-10122
35.
Wegenka UM, Lütticken C, Buschmann J, et al.
The interleukin-6-activated acute-phase response factor is antigenically and functionally related to members of the signal transducer and activator of transcription (STAT) family.
Mol Cell Biol.
1994;14:3186-3196 36. Coffer P, Lütticken C, van PA, Klop dJM, Horn F, Kruijer W. Transcriptional regulation of the junB promoter: analysis of STAT-mediated signal transduction. Oncogene. 1995;10:985-994[Medline] [Order article via Infotrieve]. 37. Tesch H, Jücker M, Klein S, et al. Hodgkin and Reed-Sternberg cells express interleukin 6 and interleukin 6 receptors. Leuk Lymphoma. 1992;7:297-303[Medline] [Order article via Infotrieve]. 38. Gouilleux GV, Debierre GF, Gouilleux F, et al. Activated Stat related transcription factors in acute leukemia. Leuk Lymphoma. 1997;28:83-88[Medline] [Order article via Infotrieve]. 39. Bromberg J, Wrzeszczynska M, Devgan G, et al. Stat3 as an oncogene. Cell. 1999;98:295-303[CrossRef][Medline] [Order article via Infotrieve].
40.
Chung CD, Liao J, Liu B, et al.
Specific inhibition of Stat3 signal transduction by PIAS3.
Science.
1997;278:1803-1805 41. Naka T, Narazaki M, Hirata M, et al. Structure and function of a new STAT-induced STAT inhibitor. Nature. 1997;387:924-929[CrossRef][Medline] [Order article via Infotrieve].
42.
Iwamoto Y, Chin YE, Peng X, Fu XY.
Identification of a membrane-associated inhibitor(s) of epidermal growth factor-induced signal transducer and activator of transcription activation.
J Biol Chem.
1998;273:18198-18204
43.
Yu CL, Meyer DJ, Campbell GS, et al.
Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein.
Science.
1995;269:81-83 44. Chaturvedi P, Sharma S, Reddy EP. Abrogation of interleukin-3 dependence of myeloid cells by the v-srconcogene requires SH2 and SH3 domains which specify activation of STATs. Mol Cell Biol. 1997;17:3295-3304[Abstract]. 45. Yu CL, Jove R, Burakoff SJ. Constitutive activation of the Janus kinase-STAT pathway in T lymphoma overexpressing the Lck protein tyrosine kinase. J Immunol. 1997;159:5206-5210[Abstract].
46.
Nelson KL, Rogers JA, Bowman TL, Jove R, Smithgall TE.
Activation of STAT3 by the c-Fes protein-tyrosine kinase.
J Biol Chem.
1998;273:7072-7077
47.
Danial NN, Pernis A, Rothman PB.
Jak-STAT signaling induced by the v-abl oncogene.
Science.
1995;269:1875-1877
48.
Zhang Q, Nowak I, Vonderheid EC, et al.
Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome.
Proc Natl Acad Sci U S A.
1996;93:9148-9153
49.
Saharinen P, Ekman N, Sarvas K, Parker P, Alitalo K, Silvennoinen O.
The Bmx tyrosine kinase induces activation of the STAT signaling pathway, which is specifically inhibited by protein kinase C delta.
Blood.
1997;90:4341-4353 50. Jücker M, Schaadt M, Diehl V, Poppema S, Jones D, Tesch H. Heterogeneous expression of proto-oncogenes in Hodgkin's disease derived cell lines. Hematol Oncol. 1990;8:191-204[Medline] [Order article via Infotrieve].
51.
Tilly H, Bastard C, Delastre T, et al.
Cytogenetic studies in untreated Hodgkin's disease.
Blood.
1991;77:1298-1304 52. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969[Medline] [Order article via Infotrieve]. 53. Krappmann D, Emmerich F, Kordes U, Scharschmidt E, Dörken B, Scheidereit C. Molecular mechanisms of constitutive NF-kappaB/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene. 1999;18:943-953[CrossRef][Medline] [Order article via Infotrieve].
54.
Wood KM, Roff M, Hay R.
Defective I 55. Fukada T, Hibi M, Yamanaka Y, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity. 1996;5:449-460[CrossRef][Medline] [Order article via Infotrieve]. 56. Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T. Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis. Immunity. 1999;11:709-719[CrossRef][Medline] [Order article via Infotrieve]. 57. Kortylewski M, Heinrich PC, Mackiewicz A, et al. Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1. Oncogene. 1999;18:3742-3753[CrossRef][Medline] [Order article via Infotrieve]. 58. Hirano T, Nakajima K, Hibi M. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev. 1997;8:241-252[CrossRef][Medline] [Order article via Infotrieve]. 59. Fukada T, Ohtani T, Yoshida Y, et al. STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J. 1998;17:6670-6677[CrossRef][Medline] [Order article via Infotrieve].
60.
Joos S, Kupper M, Ohl S, et al.
Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells.
Cancer Res.
2000;60:549-552
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  A. Navarro, T. Diaz, A. Martinez, A. Gaya, A. Pons, B. Gel, C. Codony, G. Ferrer, C. Martinez, E. Montserrat, et al. Regulation of JAK2 by miR-135a: prognostic impact in classic Hodgkin lymphoma Blood, October 1, 2009; 114(14): 2945 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lamprecht, S. Kreher, I. Anagnostopoulos, K. Johrens, G. Monteleone, F. Jundt, H. Stein, M. Janz, B. Dorken, and S. Mathas Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3{alpha} Blood, October 15, 2008; 112(8): 3339 - 3347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. A. Scheeren, S. A. Diehl, L. A. Smit, T. Beaumont, M. Naspetti, R. J. Bende, B. Blom, K. Karube, K. Ohshima, C. J. M. van Noesel, et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5: evidence that activated STAT5 is required for Hodgkin lymphomagenesis Blood, May 1, 2008; 111(9): 4706 - 4715. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. B. Ding, J. J. Yu, R. Y.-L. Yu, L. M. Mendez, R. Shaknovich, Y. Zhang, G. Cattoretti, and B. H. Ye Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas Blood, February 1, 2008; 111(3): 1515 - 1523. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Kapatai and P Murray Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma J. Clin. Pathol., December 1, 2007; 60(12): 1342 - 1349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Feys, B. Poppe, K. De Preter, N. Van Roy, B. Verhasselt, P. De Paepe, A. De Paepe, and F. Speleman A detailed inventory of DNA copy number alterations in four commonly used Hodgkin's lymphoma cell lines Haematologica, July 1, 2007; 92(7): 913 - 920. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nagel, C. Burek, L. Venturini, M. Scherr, H. Quentmeier, C. Meyer, A. Rosenwald, H. G. Drexler, and R. A. F. MacLeod Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1 Blood, April 1, 2007; 109(7): 3015 - 3023. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Sanchez-Aguilera, C. Montalban, P. de la Cueva, L. Sanchez-Verde, M. M. Morente, M. Garcia-Cosio, J. Garcia-Larana, C. Bellas, M. Provencio, V. Romagosa, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma Blood, July 15, 2006; 108(2): 662 - 668. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Brinkmann and T. F. Schulz Regulation of intracellular signalling by the terminal membrane proteins of members of the Gammaherpesvirinae. J. Gen. Virol., May 1, 2006; 87(Pt 5): 1047 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Karube, K. Ohshima, J. Suzumiya, R. Kawano, M. Kikuchi, and M. Harada Gene expression profile of cytokines and chemokines in microdissected primary Hodgkin and Reed-Sternberg (HRS) cells: high expression of interleukin-11 receptor {alpha} Ann. Onc., January 1, 2006; 17(1): 110 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dube, A. Bourdeau, K. M. Heinonen, A. Cheng, A. Lee Loy, and M. L. Tremblay Genetic Ablation of Protein Tyrosine Phosphatase 1B Accelerates Lymphomagenesis of p53-Null Mice through the Regulation of B-Cell Development Cancer Res., November 1, 2005; 65(21): 10088 - 10095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Lin, R. Lai, L. R. Chirieac, C. Li, V. A. Thomazy, I. Grammatikakis, G. Z. Rassidakis, W. Zhang, Y. Fujio, K. Kunisada, et al. Constitutive Activation of JAK3/STAT3 in Colon Carcinoma Tumors and Cell Lines: Inhibition of JAK3/STAT3 Signaling Induces Apoptosis and Cell Cycle Arrest of Colon Carcinoma Cells Am. J. Pathol., October 1, 2005; 167(4): 969 - 980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Re, R. K. Thomas, K. Behringer, and V. Diehl From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential Blood, June 15, 2005; 105(12): 4553 - 4560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. D. Khoury, L. J. Medeiros, G. Z. Rassidakis, M. A. Yared, P. Tsioli, V. Leventaki, A. Schmitt-Graeff, M. Herling, H. M. Amin, and R. Lai Differential Expression and Clinical Significance of Tyrosine-phosphorylated STAT3 in ALK+ and ALK- Anaplastic Large Cell Lymphoma Clin. Cancer Res., September 1, 2003; 9(10): 3692 - 3699. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Liu, Y. Ma, S. M. Cole, C. Zander, K.-H. Chen, J. Karras, and R. M. Pope Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival Blood, July 1, 2003; 102(1): 344 - 352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Benekli, M. R. Baer, H. Baumann, and M. Wetzler Signal transducer and activator of transcription proteins in leukemias Blood, April 15, 2003; 101(8): 2940 - 2954. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chen, L. Hutt-Fletcher, L. Cao, and S. D. Hayward A Positive Autoregulatory Loop of LMP1 Expression and STAT Activation in Epithelial Cells Latently Infected with Epstein-Barr Virus J. Virol., April 1, 2003; 77(7): 4139 - 4148. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Richardson, C. Fielding, M. Rowe, and P. Brennan Epstein-Barr Virus Regulates STAT1 through Latent Membrane Protein 1 J. Virol., April 1, 2003; 77(7): 4439 - 4443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Schwering, A. Brauninger, U. Klein, B. Jungnickel, M. Tinguely, V. Diehl, M.-L. Hansmann, R. Dalla-Favera, K. Rajewsky, and R. Kuppers Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma Blood, February 15, 2003; 101(4): 1505 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. E. Brown and N. R. Kamal The Reed-Sternberg Cell: Molecular Characterization by Proteomic Analysis with Therapeutic Implications Ann. Clin. Lab. Sci., October 1, 2002; 32(4): 339 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Burysek, T. Syrovets, and T. Simmet The Serine Protease Plasmin Triggers Expression of MCP-1 and CD40 in Human Primary Monocytes via Activation of p38 MAPK and Janus Kinase (JAK)/STAT Signaling Pathways J. Biol. Chem., August 30, 2002; 277(36): 33509 - 33517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. Skinnider and T. W. Mak The role of cytokines in classical Hodgkin lymphoma Blood, May 29, 2002; 99(12): 4283 - 4297. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
B, another transcription factor activated by a number of cytokines.